EPRX · Company research
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 16, 2026 | neutral | 0 | 0.6 |
| Trial enrollment hits its target at Eupraxia (EPRX), with interim data expected in December 2026. - Stock Titan | Trial enrollment hits its target at Eupraxia (EPRX), with interim data expected in December 2026. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Eupraxia's trial has administered over 3,000 injections with no treatment-related serious events to date. - Stock Titan | Eupraxia's trial has administered over 3,000 injections with no treatment-related serious events to date. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Can Eupraxia Pharmaceuticals stock go even higher? - Cantech Letter | Can Eupraxia Pharmaceuticals stock go even higher? Cantech Letter | View source ↗ | Cantech Letter | Oct 12, 2026 | neutral | 0 | 0.6 |
| Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis - kalkine.ca | Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis kalkine.ca | View source ↗ | kalkine.ca | Oct 12, 2026 | neutral | 0 | 0.6 |
| EUPRAXIA PHARMACEUTICALS INC (EPRX.NE) Interactive Stock Chart - Yahoo! Finance Canada | EUPRAXIA PHARMACEUTICALS INC (EPRX.NE) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX) - The Globe and Mail | Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX) The Globe and Mail | View source ↗ | The Globe and Mail | Oct 10, 2026 | neutral | 0 | 0.6 |
| Eupraxia Pharmaceuticals Inc. (EPRX.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada | Eupraxia Pharmaceuticals Inc. (EPRX.TO) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Three trial abstracts from Eupraxia (EPRX) are scheduled for October 12, 18 and 19 presentations. - Stock Titan | Three trial abstracts from Eupraxia (EPRX) are scheduled for October 12, 18 and 19 presentations. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences | Eupraxia Pharmaceuticals announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE) have been accepted for presentation at the ACG 2026 Annual Scientific Meeting in Nashville (October 9-14) and UEG Week 2026 in Barcelona (October 17-20). The presentations will showcase data on improvements in dysphagia and histopathological features persisting over 52 weeks during dose escalation. Phase 2b interim data is expected in December 2026. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences | Eupraxia Pharmaceuticals announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE) have been accepted for presentation at the ACG 2026 Annual Scientific Meeting in Nashville (October 9-14) and UEG Week 2026 in Barcelona (October 17-20). The presentations will showcase data on improvements in dysphagia and histopathological features persisting over 52 weeks during dose escalation. Phase 2b interim data is expected in December 2026. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| How EPRX Corporation (EPRX) Affects Rotational Strategy Timing - Stock Traders Daily | How EPRX Corporation (EPRX) Affects Rotational Strategy Timing Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 7, 2026 | neutral | 0 | 0.6 |
| EUPRAXIA PHARMACEUTICALS INC (EPRX.NE) latest stock news and headlines - Yahoo Finance Singapore | EUPRAXIA PHARMACEUTICALS INC (EPRX.NE) latest stock news and headlines Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 7, 2026 | neutral | 0 | 0.6 |
| Eupraxia Pharmaceuticals (TSX:EPRX) Stock Drops 13.86% After 52-Week RESOLVE Data as Phase 2b Readout Moves to December - kalkine.ca | Eupraxia Pharmaceuticals (TSX:EPRX) Stock Drops 13.86% After 52-Week RESOLVE Data as Phase 2b Readout Moves to December kalkine.ca | View source ↗ | kalkine.ca | Oct 2, 2026 | neutral | 0 | 0.6 |
| Fifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. - Stock Titan | Fifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock Price: Oct 14 Close $6.59 - Gotrade | Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock Price: Oct 14 Close $6.59 Gotrade | View source ↗ | Gotrade | Sep 9, 2026 | neutral | 0 | 0.6 |
| EPRX Stock Jumps As Traders Eye Volatile Breakout - timothysykes.com | EPRX Stock Jumps As Traders Eye Volatile Breakout timothysykes.com | View source ↗ | timothysykes.com | Sep 5, 2026 | neutral | 0 | 0.6 |
| EPRX Jumps As Traders Focus On Cash Runway And Momentum - StocksToTrade | EPRX Jumps As Traders Focus On Cash Runway And Momentum StocksToTrade | View source ↗ | StocksToTrade | Sep 5, 2026 | neutral | 0 | 0.6 |
| Eupraxia Pharmaceuticals Independent Director Acquires 1.4% More Stock - Simply Wall Street | Eupraxia Pharmaceuticals Independent Director Acquires 1.4% More Stock Simply Wall Street | View source ↗ | Simply Wall Street | Aug 23, 2026 | neutral | 0 | 0.6 |
| Eupraxia (EPRX) Watch: Finishes 0.44% Lower at $6.73 in the Latest Reading; Technical View: $6.39 and $7.07 Define the Nearby Reference Levels under the Current Snapshot - Call Resistance - siam.in | Eupraxia (EPRX) Watch: Finishes 0.44% Lower at $6.73 in the Latest Reading; Technical View: $6.39 and $7.07 Define the Nearby Reference Levels under the Current Snapshot - Call Resistance siam.in | View source ↗ | siam.in | Aug 23, 2026 | neutral | 0 | 0.6 |
| Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - Yahoo Finance | Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 10, 2026 | neutral | 0 | 0.6 |
| EPRX Forecast — Price Target — Prediction for 2027 - TradingView | EPRX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| New Analyst Forecast: $EPRX Given $25 Price Target | EPRX Stock News - Quiver Quantitative | New Analyst Forecast: $EPRX Given $25 Price Target | EPRX Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | May 21, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.